Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EBT (2016 - 2025)

Altimmune (ALT) has disclosed EBT for 16 consecutive years, with $57.9 million as the latest value for Q4 2025.

  • Quarterly EBT fell 11.24% to $57.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.5 million through Dec 2025, up 47.04% year-over-year, with the annual reading at -$3.5 million for FY2025, 47.04% up from the prior year.
  • EBT for Q4 2025 was $57.9 million at Altimmune, up from -$19.0 million in the prior quarter.
  • The five-year high for EBT was $65.2 million in Q4 2024, with the low at -$33.5 million in Q3 2021.
  • Average EBT over 5 years is -$6.8 million, with a median of -$20.2 million recorded in 2022.
  • The sharpest move saw EBT tumbled 139.6% in 2022, then soared 257.23% in 2023.
  • Over 5 years, EBT stood at $54.7 million in 2021, then tumbled by 139.6% to -$21.7 million in 2022, then skyrocketed by 257.23% to $34.1 million in 2023, then surged by 91.51% to $65.2 million in 2024, then decreased by 11.24% to $57.9 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $57.9 million, -$19.0 million, and -$22.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.